Keyword search (4,163 papers available)

"Wei DQ" Authored Publications:

Title Authors PubMed ID
1 ESOMIR: a curated database of biomarker genes and miRNAs associated with esophageal cancer Sindhoo A; Sipy S; Khan A; Selvaraj G; Alshammari A; Casida ME; Wei DQ; 37815872
CHEMBIOCHEM
2 Editorial: Computational systems immunovirology Zarei Ghobadi M; Teymoori-Rad M; Selvaraj G; Wei DQ; 37475870
CHEMBIOCHEM
3 Proteomics-based vaccine targets annotation and design of subunit and mRNA-based vaccines for Monkeypox virus (MPXV) against the recent outbreak Jin Y; Fayyaz A; Liaqat A; Khan A; Alshammari A; Wang Y; Gu RX; Wei DQ; 37116237
CONCORDIA
4 Interrogation of Bacillus anthracis SrtA active site loop forming open/close lid conformations through extensive MD simulations for understanding binding selectivity of SrtA inhibitors Selvaraj C; Selvaraj G; Mohamed Ismail R; Vijayakumar R; Baazeem A; Wei DQ; Singh SK; 34220215
BIOLOGY
5 Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19 Kaliamurthi S; Selvaraj G; Selvaraj C; Singh SK; Wei DQ; Peslherbe GH; 34209188
CHEMBIOCHEM
6 Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ; 34021862
CHEMBIOCHEM
7 Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ; 33968364
CERMM
8 Circulating miR-1246 Targeting UBE2C, TNNI3, TRAIP, UCHL1 Genes and Key Pathways as a Potential Biomarker for Lung Adenocarcinoma: Integrated Biological Network Analysis Huang S; Wei YK; Kaliamurthi S; Cao Y; Nangraj AS; Sui X; Chu D; Wang H; Wei DQ; Peslherbe GH; Selvaraj G; Shi J; 33050659
CHEMBIOCHEM

 

Title:Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights
Authors:Selvaraj GKaliamurthi SPeslherbe GHWei DQ
Link:https://pubmed.ncbi.nlm.nih.gov/34021862/
DOI:10.1007/s12539-021-00438-3
Publication:Interdisciplinary sciences, computational life sciences
Keywords:AnaphylaxisAntibodyBNT162b2COVID-19IgEMRNA vaccineMRNA-1273PEGSARS-CoV-2
PMID:34021862 Category: Date Added:2021-05-22
Dept Affiliation: CHEMBIOCHEM
1 Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University, 7141 Sherbrooke Street W, Montreal, QC, H4B1R6, Canada. gurudeeban.selvaraj@concordia.ca.
2 Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University, 7141 Sherbrooke Street W, Montreal, QC, H4B1R6, Canada.
3 The State Key Laboratory of Microbial Metabolism, College of Life Sciences and Biotechnology, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang, Shanghai, 200240, China. dqwei@sjtu.edu.cn.
4 IASIA (International Association of Scientists in the Interdisciplinary Areas), 125 Boul. de Bromont, Quebec, QC, J2L 2K7, Canada. dqwei@sjtu.edu.cn.

Description:

The Food and Drug Administration (FDA) has recently authorized the two messenger RNA (mRNA) vaccines BNT162b2 and mRNA-1273 for emergency use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the COVID-19 coronavirus disease. BNT162b2 and mRNA-1273 vaccines were developed by Pfizer-BioNTech and Moderna, respectively, in 2020. The United Kingdom, Bahrain, Canada, Mexico, United States, Singapore, Oman, Saudi Arabia, Kuwait, and European Union began their vaccination programs with the BNT162b2 vaccine, while the United States and Canada also started the mRNA-1273 vaccination program in mid December 2020. On 28th December 2020, studies reported severe allergic reactions in people who received the BNT162b2, and few people who received the mRNA-1273 vaccine. Authors of the letter thus attempt to explore possible causes of anaphylaxis following COVID-19 vaccination.





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University